(3S,3aR,8bR)-3a-(1,3-benzodioxol-5-yl)-8b-hydroxy-6,8-dimethoxy-3-phenyl-2,3-dihydrocyclopenta[b][1]benzofuran-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (3S,3aR,8bR)-3a-(1,3-benzodioxol-5-yl)-8b-hydroxy-6,8-dimethoxy-3-phenyl-2,3-dihydrocyclopenta[b][1]benzofuran-1-one
• 化学式: C₂₆H₂₂O₇
• 分子量: 446.4
• InChiKey: YCRUGMHLZHDDGT-IMDCKVJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER
  申请人：DKFZ Deutsches Krebsforschungszentrum

  公开号：EP2364148B1

  公开（公告）日：2018-07-18
• SENSITIZATION OF CANCER CELLS TO APOPTOSIS INDUCTION BY FLAVAGLINES AND 5-HYDROXY-FLAVONES
  申请人：DEUTSCHES KREBSFORSCHUNGSZENTRUM

  公开号：US20160158189A1

  公开（公告）日：2016-06-09

  The present invention relates to a combined preparation for simultaneous, separate or sequential use comprising at least one flavagline or a pharmaceutically acceptable salt thereof; and/or at least one 5-hydroxy-flavone or a pharmaceutically acceptable salt thereof; and at least one agent activating the intrinsic pathway of apoptosis for use in the treatment of cancer. The N present invention further relates to a medicament comprising the combined preparation of the present invention, as well as to a kit comprising the combined preparation or a medicament according to the present invention and a means for administering at least one of its components. Moreover, the present invention relates to a method of inhibiting a cancer cell, comprising contacting said cancer cell with the combined preparation of the present invention, and thereby inhibiting said cancer cell.
• TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY
  申请人：DEUTSCHES KREBSFORSCHUNGSZENTRUM

  公开号：US20160287553A1

  公开（公告）日：2016-10-06

  The present invention relates to an inhibitor of protein translation for use in high-dose chemotherapy and/or high-dose radiotherapy of disease; to an inhibitor of protein translation for use in a combination therapy comprising high-dose chemotherapy and/or high-dose radiotherapy of disease; and to an inhibitor of protein translation for use in preventing adverse effects of high-dose chemotherapy and/or high-dose radiotherapy or for preventing radiation syndrome in a subject. Moreover, the present invention relates to a combined preparation for simultaneous, separate or sequential use comprising at least one inhibitor of protein translation or a pharmaceutically acceptable salt thereof; and at least one chemotherapeutic agent for use in high-dose chemotherapy of disease; to the use of an inhibitor of protein translation in high-dose chemotherapy and/or high-dose radiotherapy of disease; and to a medicament for the therapy of disease which contains (i) at least one inhibitor of protein translation or a pharmaceutically acceptable salt thereof, (ii) at least one chemotherapeutic agent, and (iii) at least one pharmaceutically acceptable carrier. Further, the present invention relates to a kit comprising at least one inhibitor of protein translation and instructions on administering high-dose chemotherapy and/or instructions on administering high-dose radiotherapy in the presence of said inhibitor of protein translation; as well as to improved methods of preventing in a subject requiring high-dose chemotherapy and/or high-dose radiotherapy adverse events caused by said therapy or therapies, of improving a medical condition requiring high-dose chemotherapy and/or high-dose radiotherapy; and of treating a subject in need of high-dose chemotherapy and/or high-dose radiotherapy.
• COMBINATION THERAPY WITH A FLAVAGLINE AND 2-DEOXYGLUCOSE
  申请人：Ruprecht-Karls-Universitat Heidelberg

  公开号：US20180169123A1

  公开（公告）日：2018-06-21

  The present invention relates to a combined preparation comprising 2-deoxyglucose and a flavagline and to the use of said combined preparation as a medicament or in the treatment of cancer. Moreover, the present invention relates to a flavagline for use in a combination therapy against cancer comprising administration of 2-deoxyglucose; and to 2-deoxyglucose for use in a combination therapy against cancer comprising administration of a flavagline. Also, the present invention relates to methods for treating cancer and to processes for the preparation of a combined preparation according to the invention.
• US9387192B2
  申请人：——

  公开号：US9387192B2

  公开（公告）日：2016-07-12